Aardvark Therapeutics Expands Phase 3 HERO Trial Eligibility for ARD-101 in Prader-Willi Syndrome After FDA Protocol Alignment
Aardvark Therapeutics Inc. (NASDAQ:AARD) is one of the best young stocks with huge upside potential.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Laurion Capital Management Benjamin A. Smith | 1,034,459 | $5,451,599 | 0.09% |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.40 | 3,000 | $43,200.00 | 108,484 | 2025-12-11 | Filing | |
| $14.49 | 7,000 | $101,395.00 | 1,551,613 | 2025-12-11 | Filing | |
| $9.94 | 3,500 | $34,804.70 | 1,543,384 | 2025-09-15 | Filing | |
| $9.51 | 6,500 | $61,818.90 | 1,539,884 | 2025-09-15 | Filing | |
| $8.50 | 5,000 | $42,515.50 | 1,533,384 | 2025-09-12 | Filing |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.18 | 62,000 | $321,178.60 | 35,475 | 2026-09-11 | Filing | |
| $5.00 | 14,754 | $73,778.85 | 97,475 | 2026-09-10 | Filing |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 139,007 | $732,962 | 0% | |
| 2. | 37,538 | $197,825 | 0% | |
| 3. | 25,792 | $135,925 | 0% | |
| 4. | 24,600 | $129,642 | 0% | |
| 5. | 17,710 | $93,332 | 0% |